Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €5.21 EUR
Change Today +0.148 / 2.92%
Volume 0.0
XYXR On Other Exchanges
As of 12:18 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

raptor pharmaceutical corp (XYXR) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/1/15 - €14.57
52 Week Low
09/29/15 - €4.84
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

raptor pharmaceutical corp (XYXR) Related Bloomberg News

View More Bloomberg News

raptor pharmaceutical corp (XYXR) Related Businessweek News

No Related Businessweek News Found

raptor pharmaceutical corp (XYXR) Details

Raptor Pharmaceutical Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The company offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults, as well as in six years and older children in the United States, in the 28 member states of the European Union, Norway, Liechtenstein, and Iceland. Its clinical development programs include RP103 that is used as a treatment for Huntington's disease; RP103 as a treatment for non-alcoholic fatty liver disease in children; and RP103 as a treatment for mitochondrial disorders, including Leigh syndrome. The company’s other clinical-stage product candidates comprise Convivia, an oral formulation of 4-methylpyrazole for the treatment of acetaldehyde toxicity resulting from aldehyde dehydrogenase deficiency. Its preclinical product candidates include cysteamine dioxygenase and HepTide for the treatment of hepatocellular carcinoma and other cancers susceptible to induced lysosomal storage. Raptor Pharmaceuticals Corp. has a collaboration agreement with DaVita Clinical Research to screen blood samples from the United States patients with end-stage renal disease to identify patients with unrecognized late-onset nephropathic cystinosis. The company was founded in 2005 and is headquartered in Novato, California.

123 Employees
Last Reported Date: 03/2/15
Founded in 2005

raptor pharmaceutical corp (XYXR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $421.1K
Chief Commercial Officer
Total Annual Compensation: $114.9K
Corporate Controller
Total Annual Compensation: $210.8K
Compensation as of Fiscal Year 2014.

raptor pharmaceutical corp (XYXR) Key Developments

Raptor Pharmaceuticals Corp. Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 10:40 AM

Raptor Pharmaceuticals Corp. Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 10:40 AM. Venue: Le Parker Meridian, New York, New York, United States. Speakers: Julie Anne Smith, Chief Executive Officer, President and Director.

Raptor Pharmaceutical Provides Results from Phase 2B CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis

Raptor Pharmaceutical Corp. announced results from the Phase 2b CyNCh study, which did not meet its primary endpoint of improving nonalcoholic steatohepatitis (NASH) in children. The trial evaluated the safety and efficacy of RP103, or cysteamine bitartrate delayed-release capsules, in children with biopsy-confirmed NASH. The study did not achieve its primary endpoint defined as a two-point decrease in NAFLD Activity Score (NAS) and no worsening of fibrosis (p-value = 0.34). There were no differences in adverse events observed in children on RP103 compared to placebo. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, sponsored and conducted the CyNCh study through a Cooperative Research and Development Agreement (CRADA) with Raptor. Study investigators intend to submit the data for publication and present topline results at the upcoming American Association for the Study of Liver Diseases (AASLD) meeting being held November 13-17, 2015 in San Francisco.

Raptor Pharmaceuticals Corp. Presents at Citi 10th Annual Biotech Conference, Sep-09-2015

Raptor Pharmaceuticals Corp. Presents at Citi 10th Annual Biotech Conference, Sep-09-2015 . Venue: Mandarin Oriental New York, 80 Columbus Circle, New York, NY 10023, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XYXR:GR €5.21 EUR +0.148

XYXR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $34.67 USD +0.93
Illumina Inc $163.61 USD +6.40
View Industry Companies

Industry Analysis


Industry Average

Valuation XYXR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.7x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RAPTOR PHARMACEUTICAL CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at